On April 10, 2026 (the "Effective Date"), Sana Biotechnology, Inc. (the "Company") entered into a stock purchase agreement (the "Stock Purchase Agreement") with Mayo Clinic, pursuant to which the Company agreed to sell to Mayo Clinic, and Mayo Clinic agreed to purchase from the Company, (i) 7,507,507 shares (the "Initial Shares") of the Company's common stock, $0.0001 par value per share ("Common Stock"), at a price of $3.33 per share (the "Per Share Purchase Price"), for gross proceeds of approximately $25.0 million, and (ii) if elected by Mayo Clinic on or prior to August 31, 2026 (the "Election"), an additional 7,507,507 shares of Common Stock (the "Additional Shares," and together with the Initial Shares, the "Shares") at the Per Share Purchase Price, for additional gross proceeds of approximately $25.0 million (collectively, the "Transaction").